Rgenta Therapeutics
Rgenta Therapeutics is a clinical-stage biotechnology company headquartered at 300 TradeCenter, Woburn, Massachusetts, developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Its discovery platform mines large-scale genomics data to identify targetable RNA processing events, then designs small molecules that modulate the interactions among the spliceosome, RNA-binding regulatory proteins and RNA itself in order to shut down production of disease-driving proteins previously considered undruggable. Its lead clinical asset, RGT-61159, is an orally available modulator of MYB splicing in development for adenoid cystic carcinoma and colorectal cancer, and its RSwitch technology applies the same chemistry to tune transgene expression in AAV-delivered gene and cell therapies. Rgenta is a therapeutics developer, not a software vendor: it publishes no API, no developer portal and no machine-readable API contract of any kind.
Rgenta Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Drug Discovery.
Rgenta Therapeutics’ developer surface includes engineering blog and 8 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 1
Pricing, plans, and the legal terms of use
Company 5
The organization behind the API
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.